Marie Csete – VJRegenMed

Challenges in targeting the eye with cell therapy

Simon Ng — Tue, 26 Oct 2021 09:53:04 +0000

Marie Csete, MD, PhD, ConeSight Therapeutics, Pasadena, CA, describes issues associated with developing cell therapies for ophthalmological conditions. Subretinal delivery of cell therapies require a retinal tear, which can prolong recovery times and even in the case of successful delivery, therapeutic efficacy is not guaranteed. The level of scarring and degeneration in the eye can additionally affect treatment outcomes. Phenotyping patients with visual tests or advanced imaging techniques can address the aforementioned issues by defining a subset of patients who will most likely benefit from cell therapies. This interview took place at Meeting on the Mesa 2021.

Cell therapies for cone-rod dystrophy

Simon Ng — Tue, 26 Oct 2021 09:53:04 +0000

Marie Csete, MD, PhD, ConeSight Therapeutics, Pasadena, CA, discusses the development of cone progenitor cell therapies. Whilst advanced therapies in the ophthalmological space have mainly focused on retinal pigment epithelium (RPE) cells, developing cone-based cell therapies remain behind due to difficulties in regenerating cones from stem cells. Current advancements in cone progenitor cell therapies have been designed for cone rod dystrophies, with the hope of expansion to other indications including retinitis pigmentosa (RP) and macular degeneration. This interview took place at Meeting on the Mesa 2021.

Future developments in advanced therapies for the eye

Simon Ng — Tue, 26 Oct 2021 09:53:03 +0000

Marie Csete, MD, PhD, ConeSight Therapeutics, Pasadena, CA, talks on advancements in advanced therapies that are impacting the ophthalmological space. Induced pluripotent stem cell (iPSC)-based retinal pigment epithelium (RPE) cell products have made large strides within the field, and genetic engineering has enabled allogeneic therapies to be successfully delivered in patients. Treatment of glaucoma is also on the horizon with the development of cell therapies based on retinal ganglion cells. This interview took place at Meeting on the Mesa 2021.